 |
인쇄하기
취소
|
LG Life Sciences to commercialize next-generation influenza vaccine
LG Life Sciences (LGLS) on Tuesday announced an agreement with the US based Novavax, Inc. for the commercialization of the latter’s proprietary, recombinant virus-like-particle (VLP) vaccine technology.
Under the agreement, LGLS receives an exclusive license to manufacture, develop and commercialize influenza vaccines using Novavax’s recombinant VLP technology in Korea.
LGLS also receive...
Under the agreement, LGLS receives an exclusive license to manufacture, develop and commercialize influenza vaccines using Novavax’s recombinant VLP technology in Korea.
LGLS also receive...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.